Vectura Group (LON:VEC)‘s stock had its “hold” rating reissued by equities research analysts at Shore Capital in a report released on Monday.
Several other research analysts have also commented on the company. Peel Hunt cut their price objective on Vectura Group from GBX 160 ($2.21) to GBX 120 ($1.66) and set a “hold” rating for the company in a report on Wednesday, February 14th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Vectura Group in a report on Monday, January 15th. Royal Bank of Canada raised Vectura Group to a “sector performer” rating and set a GBX 119 ($1.64) price objective for the company in a report on Thursday, December 14th. Finally, Numis Securities reissued a “buy” rating and set a GBX 170 ($2.35) price objective on shares of Vectura Group in a report on Thursday, January 4th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of GBX 169.56 ($2.34).
Vectura Group (LON VEC) opened at GBX 78.80 ($1.09) on Monday. Vectura Group has a twelve month low of GBX 70 ($0.97) and a twelve month high of GBX 166.97 ($2.31).
About Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.